Author:
Dobbin Kevin K.,Cesano Alessandra,Alvarez John,Hawtin Rachael,Janetzki Sylvia,Kirsch Ilan,Masucci Giuseppe V.,Robbins Paul B.,Selvan Senthamil R.,Streicher Howard Z.,Zhang Jenny,Butterfield Lisa H.,Thurin Magdalena
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference36 articles.
1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi: 10.1056/NEJMoa1003466 .
2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi: 10.1056/NEJMoa1501824 .
3. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7. doi: 10.1200/jco.2014.59.0703 .
4. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62. doi: 10.1038/nature13904 .
5. Institute of Medicine. The national academies collection: reports funded by national institutes of health, transforming clinical research in the United States: challenges and opportunities: workshop summary. Washington DC: National Academies Press; 2010.
Cited by
91 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献